TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Intermittent Hypoxia and Caffeine in Infants Born Preterm

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female infants born preterm at ≤30 weeks + 6 days post menstrual age~2. Current treatment with routine caffeine~3. PMA 32 weeks + 0 days - 36 weeks + 6 days~4. Anticipated last dose of routine caffeine will be by 36 weeks + 5 days~5. At least 12 hours of breathing room air with no ventilatory support other than on room air nasal air flow therapy regardless of flow rate, or on room air and receiving nasal CPAP, and relapse not anticipated.~6. Able to tolerate enteral medications~7. It is feasible to administer the first dose of study drug no later than 36 weeks + 6 days PMA~Exclusion Criteria:~1. Intraventricular hemorrhage Grade III-IV or cystic periventricular leukomalacia~2. Current or prior treatment for seizures~3. Current or prior treatment for cardiac arrhythmias~4. Known renal or hepatic dysfunction that in the opinion of the investigator would have a clinically relevant impact on caffeine metabolism~5. Major malformation, inborn error of metabolism, chromosomal abnormality~6. Presence of a condition for which survival to discharge unlikely~7. Social, mental health, logistical or other issues that, in the opinion of the investigator, would impact the ability of the family to complete the study

- Gender: ALL
- Minimum Age: 32 Weeks
- Maximum Age: 36 Weeks
- Healthy Volunteers: f

Study Arms:
- Extended Caffeine Treatment (Type: EXPERIMENTAL): Infants in the extended caffeine treatment arm will, beginning the next day after stopping routine caffeine treatment, receive 5 mg/kg/day of caffeine base and increase to 5 mg/kg/twice-a-day (BID) of caffeine base beginning at 36 weeks + 0 days PMA and continuing the BID doses through 42 weeks + 6 days PMA.
- Placebo (Type: PLACEBO_COMPARATOR): Infants in the placebo arm will, beginning the next day after stopping routine caffeine treatment, receive the equivalent (to study drug) volume of placebo daily and increase to the equivalent (to study drug) volume placebo BID through 42 weeks + 6 days PMA.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologically confirmed metastatic adenocarcinoma of the pancreas (AJCC Stage IV). Subjects with islet cell neoplasms are excluded~* Non-measurable or measurable disease based on the RECIST criteria~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1~* Life expectancy of \> 3 months~* Hematologic function, as follows:~  * Absolute neutrophil count (ANC) ≥ 1.5 x 109/L~ * Platelet count ≥ 100 x 109/L~ * Hemoglobin ≥ 9 g/dL (transfusion independent)~* Renal function, as follows:~  * Creatinine ≤ 2.0 mg/dL~* Hepatic function, as follows:~  * Aspartate aminotransferase (AST) ≤ 2.5 x ULN or ≤ 5 x ULN if known liver metastases.~ * Alanine aminotransferase (ALT) ≤ 2.5 x ULN or ≤ 5 x ULN if known liver metastases~ * Bilirubin ≤ 2 x ULN~* INR \< 1.3 (or ≤ 3 if on warfarin for therapeutic anti-coagulation)~Exclusion Criteria:~* Prior systemic therapy for metastatic pancreatic cancer~  * Subjects who have received adjuvant treatment with gemcitabine and who had relapse metastatically are allowed~ * Subjects with advanced local disease who have received treatment with gemcitabine and in whom progression has been observed with the onset of metastases less than 6 months are excluded~* Chemotherapy and/or radiation within 4 weeks of study enrollment~* Prior monoclonal antibody therapy within 60 days of study enrollment~* Known brain or leptomeningeal disease~* History of other primary malignancy, unless:~  * Curatively resected non-melanomatous skin cancer~ * Other malignancy curatively treated with no known active disease present and no treatment administered for the last 3 years~* Active angina or Class III or IV Congestive Heart Failure (New York Heart Association CHF Functional Classification System)~* Use of any investigational product within 4 weeks of study enrollment~* Major surgery (that requires general anesthesia) within 4 weeks before study enrollment~* Women who are pregnant (confirmed by positive pregnancy test) or lactating~* Man or woman of childbearing potential not consenting to use adequate contraceptive precautions during the course of the study and for 4 weeks after the last AGS-1C4D4 and/or gemcitabine infusion administration~* Subject known to be human immunodeficiency, hepatitis B or hepatitis C virus positive~* Active serious infection not controlled with antibiotics

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1. Gemcitabine monotherapy (Type: ACTIVE_COMPARATOR): None
- 2. Gemcitabine plus AGS-1C4D4 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Low Volume PEG-Asc and Lower Volume PEG-Asc With Bisacodyl

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients between the ages of 20 and 75 years who were scheduled to undergo colonoscopy~Exclusion Criteria:~* aged more than 75 years.~* known or suspected gastrointestinal obstruction, Ileus~* severe heart failure~* uncontrolled hypertension (systolic pressure \> 170 mmHg, diastolic pressure \> 100 mmHg)~* severe constipation~* clinically significant electrolyte abnormalities~* any prior bowel resection, or significant gastroparesis.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- 2L Polyethylene glycols-Asc (Type: ACTIVE_COMPARATOR): 1 L of PEG containing ascorbic acid (PEG A) was taken at 8:00 pm on the day before the colonoscopy, followed by an extra 500 mL of water. The second 1-L of PEG containing ascorbic acid was taken 4 h before the colonoscopy examination, with an additional 500 mL of water. Each liter of preparation and the extra 500 mL water had to be consumed within 2 h of the procedure. All colonoscopies were performed between 9 am and 1 pm.
- 1L PEG-Asc plus bisacodyl (Type: ACTIVE_COMPARATOR): 10 mg bisacodyl at 9:00 pm on the day before the colonoscopy. Four hours before the colonoscopy examination, 1 L of PEG containing ascorbic acid was taken, followed by an additional 1 L of water. The preparation was completed 2 h before the examination. All colonoscopies were performed between 9 am and 1 pm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of ACTIVA BioACTIVE Versus Compomer in Restoring Dental Decay in Primary Molar Teeth

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy children with American Society of Anesthesiologists (ASA) I score from both gender aged between three and ten years~* Vital decayed deciduous molar with proximal enamel/dentine caries~* At least one decayed tooth on each side of the mouth (split mouth)~* Pt is treatable in the dental chair~* Parents agreed to participate in the study and signed the informed consent~Exclusion Criteria:~* Patients with medical conditions or systemic disease~* Anxious or uncooperative patients who are not treatable in the dental chair~* Any symptoms like: pain, swelling, abscess or fistula.~* Extensive caries, dental developmental disturbance, pathological mobility, pulp exposure or indication for pulp therapy~* Patients with one decayed tooth in the whole mouth (not split mouth)

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 10 Years
- Healthy Volunteers: t

Study Arms:
- ACTIVA™ BioACTIVE (Type: EXPERIMENTAL): Restoring cavity using ACTIVA filling material
- Compomer (Type: ACTIVE_COMPARATOR): Restoring cavity using compomer filling material

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Expiratory Muscle Strength Training for Improving Communication in ALS

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of ALS~* Within the early stages of disease progression (i.e., able to talk, breathe, and eat independently)~* Speaker of English~* Have a family member/caregiver willing to assist as needed~* Have access to an electronic device and internet for tele-health~Exclusion Criteria:~* A history of neurological disease (besides ALS)~* A history of asthma or respiratory problems (e.g., COPD, emphysema)~* A history of head, neck, or chest surgery (except mastectomy)~* A history of smoking within the last 5 years~* Reliance on mechanical ventilation (including CPAP)

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Expiratory Muscle Strength Training (Type: EXPERIMENTAL): All participants will forcefully breathe out into an Expiratory Muscle Strength Training device (EMST-150) 25 times per day for 6 weeks. The EMST device will be set at a moderate intensity level (50% of each participant's maximum expiratory pressure).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial in Periodontal Tissue Regeneration Using Fibroblast Growth Factor-2

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosed as 2- or 3-walled vertical intrabony defect \>=3 mm deep from the top of the remaining alveolar bone~* with mobility of the tooth of degree 2 or less~* with width of attached gingiva appropriate for Guided Tissue Regeneration~Exclusion Criteria:~* concomitant administration of adrenal cortical steroid within 4 wks after the surgery~* administeration of calcium antagonist during the 4 weeks preceding administration of the investigational drug~* coexisting malignant tumour or history of the same~* coexisting diabetes (HbA1C \>= 6.5%)~* an extremely poor nutritional condition (serum albumin concentration \<2 g/dL)~* pregnancy or lactation

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- P (Type: PLACEBO_COMPARATOR): None
- L (Type: EXPERIMENTAL): low dose (0.03 %)
- M (Type: EXPERIMENTAL): medium dose (0.1 %)
- H (Type: EXPERIMENTAL): high dose (0.3 %)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy in Treating Patients With Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed prostate cancer~  * T1b-T3a, N0, M0 (stage II or III)~* Prostate-specific antigen at least 50 ng/mL~PATIENT CHARACTERISTICS:~Age:~* Not specified~Performance status:~* WHO 0-1~Life expectancy:~* Not specified~Hematopoietic:~* WBC greater than 4,000/mm\^3~* Platelet count greater than 100,000/mm\^3~* Hemoglobin greater than 11 g/dL~Hepatic:~* Not specified~Renal:~* Not specified~Other:~* No significant past medical history that would preclude radical radiotherapy~* No condition that would preclude standard radiotherapy~* No hip prosthesis~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* Not specified~Endocrine therapy:~* No prior androgen deprivation therapy~Radiotherapy:~* No prior pelvic radiotherapy~Surgery:~* No prior radical prostatectomy

- Gender: MALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed cancer of the urothelium (renal pelvis, ureter, bladder, or urethra)~  * Any of the following types:~    * Transitional cell carcinoma (TCC)~   * Mixed histologies containing a component of TCC~   * Non-TCC of the urothelium (renal pelvis, ureter, bladder, or urethra)~* Progressing regional or metastatic disease~* Measurable disease~* No clinical evidence of CNS metastases~* No evidence of clinically significant (by physical exam or plain film) third-space fluid collections (pleural effusions or ascites)~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* ECOG 0-2~Life expectancy~* Not specified~Hematopoietic~* Granulocyte count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~* Hemoglobin at least 9 g/dL~Hepatic~* AST no greater than 3 times upper limit of normal (ULN)~* Bilirubin no greater than 1.5 times ULN~Renal~* Creatinine clearance at least 45 mL/min~Cardiovascular~* No history of severe cardiovascular disease (i.e., American Heart Association class III or IV heart disease)~* No uncontrolled congestive heart failure~* No ventricular dysrhythmias~Other~* Not pregnant or nursing~* Fertile patients must use effective contraception~* No active unresolved infection~* No other prior malignancy unless curatively treated and disease free for an appropriate (disease-specific) period of time~* Able and willing to receive folic acid and cyanocobalamin supplementation~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No prior systemic biologic response modifier therapy~Chemotherapy~* No prior systemic chemotherapy for metastatic disease~* More than 1 year since prior neoadjuvant or adjuvant chemotherapy~Endocrine therapy~* Not specified~Radiotherapy~* At least 4 weeks since prior radiotherapy and recovered~* No prior pelvic radiotherapy~* No concurrent radiotherapy~Surgery~* At least 4 weeks since prior major surgery and recovered~Other~* More than 7 days since prior parenteral antibiotics~* No salicylates for 2 days before, during, and for 2 days after administration of pemetrexed disodium~* No nonsteroidal anti-inflammatory drugs for at least 5 days before, during, and for 2 days after administration of pemetrexed disodium

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Pemetrexed Disodium and Gemcitabine (Type: EXPERIMENTAL): Pemetrexed disodium 500 mg/m2 followed by gemcitabine 1000 mg/m2 on day 1 and gemcitabine 1000 mg/m2 on day 8 of a 21-day cycle for a maximum of 6 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Radiofrequency Renal Denervation in Drug Resistant Hypertension

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 and ≤ 80 years at time of randomization~* Informed consent~* Treatment with full doses of 3 or more anti-hypertensive medications of different classes, of which one is a diuretic.~* Office Systolic BP (SBP) ≥ 160 mmHg or Diastolic BP (DBP) ≥ 100 mmHg~Exclusion Criteria:~* An estimated glomerular filtration rate (eGFR) of \< 30 mL/min/1.73 m2~* Ambulatory Blood Pressure Monitoring (ABPM) 24 hour average SBP \< 135 mmHg or DBP \< 85 mmHg~* Symptomatic(secondary) hypertension~* Severe renal artery stenosis or renal arteries abnormalities~* Individual is pregnant, nursing or planning to be pregnant~* Severe hepatic dysfunction~* Any other clinically important renal, hematological, metabolic, neurological, gastrointestinal, hepatic or pulmonary disorders or dysfunctions preventing study participation (investigator's assessment)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Renal denervation (Type: EXPERIMENTAL): All eligible patients undergo bilateral radiofrequency sympathetic renal denervation using endocardial ablation system: after standard renal angiography using femoral access a small size endocardial ablation catheter (5-6 F, 4 mm electrode) is inserted into renal artery and 4-8 point ablations are performed consecutively from distal part to aorta with 3-4 mm step and 90 degrees rotation on the upper, lower, front and back aspects of the artery to get circumferential coverage, then the procedure is repeated on the other side.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Communication Tool to Assist Severely Injured Older Adults

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Patients~Inclusion Criteria:~* Traumatically injured patients 50 and older admitted to the ICU~Exclusion Criteria:~* Surgeons will have an opportunity to exclude a patient or family who, in the physician's judgment, would not be an appropriate participant~* Patients with a Physician Orders for Life-Sustaining Medical Treatment (POLST) or Medical Orders for Life-Sustaining Medical Treatment (MOLST) form on file in their medical record that specifies that the patient or their decision maker wishes them to receive no intervention~* Patients with an isolated head injury as defined by a Head Abbreviated Injury Scale (AIS) score of 2 or less and an External AIS score of 1 or 0 and a Glasgow Coma Scale (GCS) score of 15. This serves to exclude the mildly traumatically brain injured patients with minimal external injuries who require ICU-level monitoring for a short period of time only~Family Members~Inclusion Criteria:~* N/A~Exclusion Criteria:~* We will exclude patients whose family members do not speak English~* Under the age of 18~* Lack decision making capacity (DMC)~* Have a severe hearing or vision impairment.~Surgeons~Inclusion Criteria:~-N/A~Exclusion Criteria:~* Care providers who do not directly provide primary trauma care in the ICU~* Residents who have not had at least 5 years of postgraduate training~* Trauma consultants including for example, neurosurgeons, orthopedic surgeons, and otolaryngologists~Nurses~Inclusion Criteria:~* The nurse responsible for care of the enrolled patient at 3 days post-admission will be invited to complete a Quality of Communication (QOC) survey assessment~Exclusion Criteria:~* N/A

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Best Case/Worst Case communication tool (Type: EXPERIMENTAL): The patient's enrolled surgeon will have completed training on the Best Case/Worst Case communication tool and will be encouraged to use it with the patient.
- Usual Care (Type: NO_INTERVENTION): Usual care typically includes informed consent and a surgeon-directed deliberative phase in which surgeons present their own evaluation of the trade-offs and goals of the proposed intervention.Usual care also consists of daily updates with patient and family, describing each new problem as it arises and what will be done to treat it, regardless of how this fits into the patient's overall prognosis or health trajectory.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete